BMD T-Score Classification (WHO Criteria)

About

The T-score is a statistical measure that compares an individual's bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) to that of a healthy young adult reference population of the same sex, at the age of peak bone mass (approximately 25–30 years). It is expressed as the number of standard deviations above or below the young adult mean. The WHO classification was established in 1994 by a working group led by Dr. John Kanis, based on the relationship between BMD and fracture risk in postmenopausal women. The four diagnostic categories are: Normal (T-score ≥ −1.0), Osteopenia or Low Bone Mass (T-score between −1.0 and −2.5), Osteoporosis (T-score ≤ −2.5), and Severe or Established Osteoporosis (T-score ≤ −2.5 with one or more fragility fractures). This classification has become the global standard for osteoporosis diagnosis and is endorsed by the International Society for Clinical Densitometry (ISCD), the National Osteoporosis Foundation (NOF), and the WHO Collaborating Centre for Metabolic Bone Diseases. The T-score is used for femoral neck, total hip, and lumbar spine measurements. Each 1 SD decrease in T-score approximately doubles the risk of fragility fracture. Importantly, the T-score is only validated for use in postmenopausal women and men aged 50 years and older. For younger individuals, the Z-score (comparison to age-matched peers) should be used instead. Evidence level: Grade A, supported by extensive prospective cohort data.

Formula

T-score = (Patient BMD - Young Adult Mean BMD) / Young Adult SD

The T-score formula is: T = (Patient's BMD − Mean BMD of young adult reference population) ÷ Standard Deviation of the reference population. For example, a patient with femoral neck BMD of 0.650 g/cm², where the young adult reference mean is 0.850 g/cm² and the SD is 0.120 g/cm²: T = (0.650 − 0.850) ÷ 0.120 = (−0.200) ÷ 0.120 = −1.67. This T-score of −1.67 falls within the osteopenia range (−1.0 to −2.5). The NHANES III database provides the reference data for the US population, while other countries may use their own reference databases. ISCD recommends using a uniform Caucasian (white female or white male) reference for consistency across populations. The T-score must be interpreted with attention to the skeletal site — the lumbar spine, femoral neck, and total hip are the standard measurement sites. The lowest T-score among these three sites is typically used for diagnosis. A T-score of −2.5 corresponds approximately to a BMD 2.5 SD below the young adult mean, which identifies approximately 30% of postmenopausal women as having osteoporosis. Each SD decrease doubles the fracture risk. Importantly, the T-score is a diagnostic tool, not a treatment threshold in isolation — the FRAX tool (fracture risk assessment algorithm) integrates T-score with clinical risk factors (age, sex, BMI, prior fracture, parental hip fracture, smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis, and alcohol intake) to calculate 10-year probability of major osteoporotic fracture and hip fracture. Treatment decisions should be based on the combination of T-score, FRAX probability, and clinical judgment.

Score Interpretation

BMD measurement by DXA and T-score classification is the gold standard for osteoporosis diagnosis, endorsed by the WHO, ISCD, NOF, and the American College of Physicians (ACP). The WHO classification is used worldwide to identify patients at risk for fragility fractures — osteoporotic fractures affect approximately 9 million people annually worldwide, with hip fractures alone costing healthcare systems billions of dollars. The National Osteoporosis Foundation recommends BMD testing for all women aged 65 and older and men aged 70 and older, as well as younger postmenopausal women and men aged 50–69 with clinical risk factors. The ACP guidelines (2017) recommend pharmacologic treatment for women with osteoporosis (T-score ≤ −2.5) and for women with osteopenia (T-score −1.0 to −2.5) who have high FRAX scores (≥3% for hip fracture or ≥20% for major osteoporotic fracture). The Endocrine Society guidelines similarly endorse this approach. Early diagnosis through BMD screening and treatment with bisphosphonates (alendronate, risedronate, zoledronic acid), denosumab, or anabolic agents (teriparatide, romosozumab) can reduce vertebral fracture risk by 30–70% and hip fracture risk by 40–50%. Clinical decision-making integrates the T-score with FRAX probability, prior fracture history, and secondary causes of bone loss including glucocorticoid therapy, hypogonadism, hyperparathyroidism, hyperthyroidism, gastrointestinal malabsorption, chronic kidney disease, and certain medications (SSRIs, PPIs, thiazolidinediones). Serial BMD monitoring every 1–2 years during treatment assesses response to therapy. A significant change is defined as a >3–6% change in BMD at the lumbar spine or >5–8% at the hip depending on the DXA machine precision. The T-score is also used as a component of the FRAX and Garvan fracture risk tools.

Reference Ranges